Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats
Highlights
► DATR is a promising agent for cancer therapy. ► The toxicity of DATR in combination with traditional chemotherapeutics was studied. ► This work will provide guidance to the clinical applications of DATR.
Introduction
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been identified as a powerful activator of programmed cell death, or apoptosis, in tumour cells, while sparing normal cells (Walczak et al., 1999, Ashkenazi et al., 1999, Ganten et al., 2005). Because of its wide range of antitumor activity in preclinical models, TRAIL has been studied for several years as a promising agent for cancer therapy. In recent years, with the increasing knowledge of TRAIL, combinations with targeted agents are considered to be an option to increase the efficacy of TRAIL therapy. The antitumor activity of TRAIL alone and in combination with chemotherapy has been demonstrated in several mouse xenograft models of human cancers, including colorectal (Ashkenazi et al., 1999), glioma (Roth and Weller, 1999), and breast (Walczak et al., 1999). Thus the synergetic toxicology of TRAIL in combination with traditional chemotherapy or radiotherapy attracts more and more attention.
The recombinant soluble human TRAIL mutant (DATR), recently investigated by Chengdu Diao Pharmaceutical Group Co., Ltd. (Chengdu, China), is a recombinant human 114-281 peptide of wild-type TRAIL without Pro at site 119 and Glu at site 120 (Zou et al., 2010, Zhang et al., 2011). DATR has the similar distribution, but higher concentration in tumor tissues as compared with the wild type TRAIL; furthermore, the pharmacokinetic half-life of DATR is 108 ± 12 min at the dose of 5 mg/kg (Wang et al., 2010), while the wild type TRAIL is 23 ± 6.6 min (Kelley et al., 2001). Drugs with a longer half-time will be used with lower dosage and prolonged dosing interval at the same effectiveness and thereby the side effects will be decreased. Our previous study showed that liver, renal and haematological systems might be the toxic effectors of DATR (Zou et al., 2010, Zhang et al., 2011).
The purpose of the present study was to evaluate the toxicity of DATR in combination with traditional chemotherapeutics, including irinotecan, polyene paclitaxel and oxaliplatin. This work will provide guidance to the clinical applications of DATR.
Section snippets
Chemicals
DATR and TRAIL were provided by Chengdu Diao Pharmaceutical Group Co., Ltd. (Chengdu, China) and stored at −20 °C.
Polyene paclitaxel was supplied by Shanghai PharmLab Co., Ltd. (Shanghai, China) and stored at 4 °C; irinotecan and oxaliplatin were supplied by Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, China) and stored at 4 °C.
Animals
One hundred and forty Sprague-Dawley rats (70 males and 70 females), aged 5–7 weeks, were provided by Sino-British Sippr/BK LAB Animal Co., Ltd. All rats were housed at
Results
Of all the indexes examined, only significant changes are listed or described throughout the paper.
Discussion
TRAIL has attracted great interest as a promising agent for cancer treatment (Pitti et al., 1996, Wiley et al., 1995). Previous in vivo studies showed that, like TRAIL, both DATR (unpublished) and its closely related analogue possess antitumor activity (Wiley et al., 1995).
Apart from the use of DATR as a monotherapy, combinations with traditional chemotherapeutics are potentially more valuable. An increasing number of possible rationalized TRAIL combination therapies are being tested to enhance
Conflict of interest
There is no conflict of interest.
Acknowledgments
This work was supported by grants from Chengdu Diao Pharmaceutical Group Co., Ltd. (Chengdu, China). We would like to thank Professor Yimin Dai for his excellent technical assistance with the histopathology analysis.
References (25)
- et al.
Apoptosis pathway-targeted drugs-from the bench to the clinic
Biochim. Biophys. Acta
(2004) - et al.
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
J. Biol. Chem.
(1996) - et al.
Identification and characterization of a new member of the TNF family that induces apoptosis
Immunity
(1995) - et al.
Preclinical toxicity of DATR, a recombinant soluble human TRAIL mutant, in rats and cynomolgus monkeys
Regul. Toxicol. Pharm.
(2011) - et al.
Safety and antitumor activity of recombinant soluble Apo2 ligand
J. Clin. Invest.
(1999) - et al.
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
Clin. Cancer Res.
(2005) - et al.
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP
Mol. Cancer Ther.
(2005) - et al.
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
Hepatology
(2005) - et al.
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin’s lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death
Clin. Cancer Res.
(2006) - et al.
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy- camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
Cancer Res.
(1993)
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Nat. Rev. Drug Discov.
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety
J. Pharmacol. Exp. Ther.
Cited by (2)
Preclinical safety assessment of antipyrine combined with lidocaine hydrochloride as ear drops
2019, Regulatory Toxicology and PharmacologyCitation Excerpt :The parameters involved: specific gravity, pH, WBC, nitrite, protein, glucose, ketones, urobilinogen, bilirubin and occult blood. Bone marrow examination was performed by smearing onto carrier plates as described in our previous article (Zou et al., 2012). Upon dissection, the thighbones of rats were dislodged and the bone marrow was extruded onto a carrier plate, where it was smeared in a uniform fashion.
- 1
These authors contributed equally to this work.